CONMED Corp. Stock
CONMED Corp. Stock
A very strong showing by CONMED Corp. today, with an increase of €4.20 (10.400%) compared to yesterday's price.
Our community is currently high on CONMED Corp. with 3 Buy predictions and 1 Sell predictions.
However, we have a potential of -8.07% for CONMED Corp. as the target price of 41 € is below the current price of 44.6 €.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for CONMED Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of CONMED Corp. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of CONMED Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| CONMED Corp. | 10.400% | 5.263% | 36.054% | -9.502% | 14.286% | -61.538% | -64.912% |
| Haemonetics Corp. | 1.340% | 7.092% | 14.394% | - | 10.219% | - | - |
| Bio-Rad Labs Inc. A | 3.260% | 4.601% | 11.494% | 18.149% | 12.834% | -20.881% | -53.810% |
| Penumbra Inc | 0.860% | -0.783% | 0.578% | 33.942% | 4.580% | 19.060% | 26.063% |
Comments
CONMED (CNMD) had its "underperform" rating reaffirmed by Bank of America Corporation. They now have a $40.00 price target on the stock.
Show more
Ratings data for CNMD provided by MarketBeat
CONMED (CNMD) was downgraded by Wall Street Zen from "strong-buy" to "buy".
Show more
Ratings data for CNMD provided by MarketBeat
CONMED (CNMD) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for CNMD provided by MarketBeat
News
CONMED Q2 Earnings Call Highlights
Key Points
- Interested in CONMED Corporation? Here are five stocks we like better.
- CONMED delivered better-than-expected Q2 results: Organic sales rose 6%, adjusted EPS increased 20% to $1.38
